LLY logo Eli Lilly and Company +
Eli Lilly and Company
+

Eli Lilly and Company (LLY) Business News

Track Eli Lilly and Company in real time with a live news feed covering Eli Lilly and Company stock news, official press releases, company announcements, and an archive of historical Eli Lilly and Company news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection
7:00 AM | Thursday | May 14, 2026 PRNewsWire

Lilly and UNICEF collaborate to give millions of children a healthier start

News Thumbnail
7:00 AM | Thursday | May 14, 2026 PRNewsWire

Lilly and UNICEF collaborate to give millions of children a healthier start

News Thumbnail
12:00 PM | Tuesday | May 12, 2026 PRNewsWire

In honor of its 150th anniversary, Eli Lilly and Company commits to support community organizations aiming to provide 500,000 meals and cold storage for 150 food pantries

News Thumbnail
12:43 PM | Monday | May 11, 2026 Business Wire

Centessa Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Centessa Pharmaceuticals plc - CNTA

News Thumbnail
9:00 AM | Wednesday | May 6, 2026 PRNewsWire

Lilly commits additional $4.5 billion across Indiana manufacturing sites, opens first dedicated genetic medicine facility

News Thumbnail
6:45 AM | Tuesday | May 5, 2026 PRNewsWire

Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 to demonstrate durable disease clearance in ulcerative colitis through four years

News Thumbnail
11:11 AM | Monday | May 4, 2026 PRNewsWire

Lilly declares second-quarter 2026 dividend

News Thumbnail
6:45 AM | Thursday | Apr 30, 2026 PRNewsWire

Lilly reports first-quarter 2026 financial results, raises full year guidance, and highlights momentum of new medicines

News Thumbnail
6:45 AM | Monday | Apr 27, 2026 PRNewsWire

Lilly to acquire Ajax Therapeutics to advance outcomes for patients with myelofibrosis and polycythemia vera

News Thumbnail
9:00 AM | Monday | Apr 20, 2026 PRNewsWire

Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies

News Thumbnail
10:00 AM | Thursday | Apr 16, 2026 PRNewsWire

Lilly confirms date and conference call for first-quarter 2026 financial results announcement

News Thumbnail

Lilly and UNICEF collaborate to give millions of children a healthier start

PRNewsWire

7:00 AM | Thursday | May 14, 2026

news photo
Loading...

Six-year initiative to improve non-communicable disease prevention and care for children in low- and middle-income countries NEW YORK and INDIANAPOLIS, May 14, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and UNICEF USA announced today a collaboration aiming to improve non-communicable disease (NCD) prevention and care for children, reaching over 30 million young people and caregivers across 21 low- and middle-income countries. Marking its 150th anniversary, Lilly is committing $50 million to UNICEF USA, supporting UNICEF's efforts to strengthen primary healthcare systems to better prevent, detect and manage NCDs such as diabetes, congenital heart disease, sickle cell disease and respiratory illness in children and adolescents.

Read full article redirect
7:00 AM | Thursday | May 14, 2026

Lilly and UNICEF collaborate to give millions of children a healthier start

PRNewsWire

Six-year initiative to improve non-communicable disease prevention and care for children in low- and middle-income countries NEW YORK and INDIANAPOLIS, May 14, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and UNICEF USA announced today a collaboration aiming to improve non-communicable disease (NCD) prevention and care for children, reaching over 30 million young people and caregivers across 21 low- and middle-income countries. Marking its 150th anniversary, Lilly is committing $50 million to UNICEF USA, supporting UNICEF's efforts to strengthen primary healthcare systems to better prevent, detect and manage NCDs such as diabetes, congenital heart disease, sickle cell disease and respiratory illness in children and adolescents.

Read full article arrow
News Thumbnail
7:00 AM | Thursday | May 14, 2026

Lilly and UNICEF collaborate to give millions of children a healthier start

PRNewsWire

Six-year initiative to improve non-communicable disease prevention and care for children in low- and middle-income countries NEW YORK and INDIANAPOLIS, May 14, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and UNICEF USA announced today a collaboration aiming to improve non-communicable disease (NCD) prevention and care for children, reaching over 30 million young people and caregivers across 21 low- and middle-income countries. Marking its 150th anniversary, Lilly is committing $50 million to UNICEF USA, supporting UNICEF's efforts to strengthen primary healthcare systems to better prevent, detect and manage NCDs such as diabetes, congenital heart disease, sickle cell disease and respiratory illness in children and adolescents.

Read full article arrow
News Thumbnail
12:00 PM | Tuesday | May 12, 2026

In honor of its 150th anniversary, Eli Lilly and Company commits to support community organizations aiming to provide 500,000 meals and cold storage for 150 food pantries

PRNewsWire

Through charitable support of HATCH, United Way Worldwide, United Way of Central Indiana and the Pacers Foundation, the initiative supports efforts to expand access to protein-rich food across communities nationwide, including the creation of infrastructure to deliver an estimated five million meals annually for years to come. INDIANAPOLIS, May 12, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced an initiative to support nationwide nutritious food distribution as part of the company's 150th anniversary, through charitable support of trusted community organizations in the United States.

Read full article arrow
News Thumbnail
12:43 PM | Monday | May 11, 2026

Centessa Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Centessa Pharmaceuticals plc - CNTA

Business Wire

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Centessa Pharmaceuticals plc (NasdaqGS: CNTA) to Eli Lilly and Company (NYSE: LLY). Under the terms of the proposed transaction, shareholders of Centessa will receive $38.
00 in cash per share plus one non-transferrable contingent value right entitling the holder to receive up to an aggregate of.

Read full article arrow
News Thumbnail
9:00 AM | Wednesday | May 6, 2026

Lilly commits additional $4.5 billion across Indiana manufacturing sites, opens first dedicated genetic medicine facility

PRNewsWire

Lilly's capital commitments to expand manufacturing in its home state now total $21 billion since 2020 Lilly Lebanon Advanced Therapies opens as company's first dedicated genetic medicine manufacturing facility LEBANON, Ind., May 6, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced an additional $4.5 billion investment across two of its three Lebanon sites—bringing the company's total Indiana capital expansion commitments since 2020 to more than $21 billion.

Read full article arrow
News Thumbnail
6:45 AM | Tuesday | May 5, 2026

Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 to demonstrate durable disease clearance in ulcerative colitis through four years

PRNewsWire

In LUCENT-3, more than 60% of patients who achieved disease clearance at one year maintained it after four years of continuous Omvoh treatment Disease clearance is a high clinical bar in UC requiring simultaneous symptomatic, endoscopic and histologic remission INDIANAPOLIS, May 5, 2026 /PRNewswire/ -- New long-term data from Eli Lilly and Company (NYSE: LLY) show patients with moderately to severely active ulcerative colitis (UC) treated with Omvoh (mirikizumab-mrkz) achieved durable disease clearance through four years of continuous treatment. In the LUCENT-3 open-label extension study, 63.5% of Omvoh-treated patients who achieved disease clearance at one year sustained it at four years.

Read full article arrow
News Thumbnail
11:11 AM | Monday | May 4, 2026

Lilly declares second-quarter 2026 dividend

PRNewsWire

INDIANAPOLIS, May 4, 2026 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2026 of $1.73 per share on outstanding common stock. The dividend is payable on June 10, 2026, to shareholders of record at the close of business on May 15, 2026.

Read full article arrow
News Thumbnail
6:45 AM | Thursday | Apr 30, 2026

Lilly reports first-quarter 2026 financial results, raises full year guidance, and highlights momentum of new medicines

PRNewsWire

Revenue in Q1 2026 increased 56% to $19.8 billion primarily driven by volume growth, partially offset by lower realized prices from Mounjaro and Zepbound. Q1 2026 EPS increased by 170% to $8.26 on a reported basis and increased by 156% to $8.55 on a non-GAAP basis.

Read full article arrow
News Thumbnail
6:45 AM | Monday | Apr 27, 2026

Lilly to acquire Ajax Therapeutics to advance outcomes for patients with myelofibrosis and polycythemia vera

PRNewsWire

Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026 Based on its unique mode of binding JAK2, AJ1-11095 has the potential to deliver deeper and more durable disease control than approved therapies for myelofibrosis and polycythemia vera Acquisition builds on Lilly's established capabilities in blood cancers INDIANAPOLIS and NEW YORK and CAMBRIDGE, Mass., April 27, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Ajax Therapeutics, Inc. ("Ajax"), a biopharmaceutical company developing next generation JAK inhibitors for patients with myeloproliferative neoplasms (MPNs), today announced a definitive agreement for Lilly to acquire Ajax.

Read full article arrow
News Thumbnail
9:00 AM | Monday | Apr 20, 2026

Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies

PRNewsWire

Kelonia's lead program, KLN-1010, is a potentially first-in-class lentiviral in vivo CAR-T therapy currently in Phase 1 for relapsed/refractory multiple myeloma with clinical data recently highlighted in the 2025 ASH Annual Meeting plenary session Acquisition expands Lilly's genetic medicine capabilities with a novel in vivo gene delivery and integration technology that has potential for broad applicability INDIANAPOLIS and BOSTON, Mass., April 20, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Kelonia Therapeutics, Inc. ("Kelonia"), a clinical-stage biotechnology company pioneering in vivo gene delivery, today announced a definitive agreement for Lilly to acquire Kelonia.

Read full article arrow
News Thumbnail
10:00 AM | Thursday | Apr 16, 2026

Lilly confirms date and conference call for first-quarter 2026 financial results announcement

PRNewsWire

INDIANAPOLIS, April 16, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2026 financial results on April 30, 2026. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.

Read full article arrow
News Thumbnail